LIF antibody

Catalog No. ABIN2665228

Product Details anti-LIF Antibody

Target: LIF (Leukemia Inhibitory Factor (LIF))

Reactivity: Human, Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This LIF antibody is un-conjugated

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography.

Clone: M1506B09

Isotype: IgG2a

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for LIF

Target: LIF (Leukemia Inhibitory Factor (LIF))

Alternative Name: LIF (LIF Products)

Synonyms: CDF antibody, DIA antibody, HILDA antibody, MLPLI antibody, LIF, interleukin 6 family cytokine antibody, leukemia inhibitory factor antibody, LIF antibody, Lif antibody

Background: Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that belongs to the IL-6 receptor family. It binds to a heterodimeric membrane receptor made up of a LIF-specific subunit, gp190, and the subunit gp130. The LIF complex receptor signals though STAT3 and JAK kinases. LIF expression has been observed in various tissues including the thymus, lung, and neuronal tissue. LIF displays diverse biological effects, but is best known for its ability to inhibit the differentiation of embryonic stem cells in mice and contributes to stem cell self-renewal. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, as well as the induction of neuronal cell differentiation. It also regulates mesenchymal to epithelial conversion during kidney development, and also may have a role in immune tolerance at the maternal-fetal interface. LIF can be upregulated by pro-inflammatory cytokines such as TNF-α and IL-17. Elevated levels of LIF have been found in cases of rheumatoid arthritis, neural injury, systemic inflammation, and tuberculosis.

Pathways: JAK-STAT Signaling, Positive Regulation of Peptide Hormone Secretion, Negative Regulation of Hormone Secretion, Stem Cell Maintenance, Growth Factor Binding